National Bank of Canada FI Reduces Holdings in Gilead Sciences, Inc. $GILD

National Bank of Canada FI reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,287,512 shares of the biopharmaceutical company’s stock after selling 338,738 shares during the quarter. National Bank of Canada FI owned about 0.10% of Gilead Sciences worth $142,744,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Activest Wealth Management boosted its position in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the 2nd quarter worth approximately $27,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth approximately $30,000. Finally, Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 2.3%

GILD stock opened at $120.40 on Monday. The stock has a market capitalization of $149.38 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The company has a fifty day moving average of $121.89 and a 200-day moving average of $115.81. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is 48.99%.

Analysts Set New Price Targets

GILD has been the topic of a number of research reports. Wolfe Research raised their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Truist Financial assumed coverage on shares of Gilead Sciences in a research report on Monday, November 24th. They set a “buy” rating and a $140.00 price objective on the stock. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research note on Wednesday, December 10th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, TD Cowen boosted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $131.13.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the transaction, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. This represents a 1.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 130,257 shares of company stock worth $15,991,492. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.